Home/Filings/4/0001610618-22-000019
4//SEC Filing

Daruwala Paul 4

Accession 0001610618-22-000019

CIK 0001610618other

Filed

Apr 3, 8:00 PM ET

Accepted

Apr 4, 5:04 PM ET

Size

7.1 KB

Accession

0001610618-22-000019

Insider Transaction Report

Form 4
Period: 2022-03-31
Daruwala Paul
Chief Medical Officer
Transactions
  • Award

    Common Stock

    2022-03-31+50,000237,298 total
  • Award

    Employee Stock Option (right to buy)

    2022-03-31+100,000100,000 total
    Exercise: $0.83Exp: 2032-03-30Common Stock (100,000 underlying)
Footnotes (2)
  • [F1]Represents time-based Restricted Stock Units (RSUs) granted on March 31, 2022. All RSUs vest in three equal annual installments, with 1/3 vesting on each of March 10, 2023, 2024, and 2025, subject to continuous service through each such vesting date.
  • [F2]The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of March 31, 2022.

Issuer

Cidara Therapeutics, Inc.

CIK 0001610618

Entity typeother

Related Parties

1
  • filerCIK 0001639144

Filing Metadata

Form type
4
Filed
Apr 3, 8:00 PM ET
Accepted
Apr 4, 5:04 PM ET
Size
7.1 KB